At the Cannes Lions Health festival this weekend, pharma's marketing gambles move into the spotlight.
AbbVie is in court facing the first of 4,100 defendants in a class action alleging its testosterone drug AndroGel caused cardiovascular problems.
CAR-T and TCR therapies have seen a whirlwind few years. Is 2017 set to be the year we see a CAR-T therapy approved? On a mission to find out, we sat down with…
The FDA issued its first untitled letter of the year for promotional infractions to scold Orexigen Therapeutics for infractions in a Contrave TV ad.
An ad campaign sponsored by Avanir featuring neurological condition PBA has helped fuel the controversy over how DTC advertising fosters the use of pricey meds.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
It's déjà vu in the pharma TV ad spending world. April's top spenders were almost a repeat from the previous month, with four of the five top brands…
We selected our top DTC ad picks for the year. Some impressed us with creativity, while others broke new ground or proved particularly effective.
Survivors are at the heart of AstraZeneca's new DTC campaign for clot-fighter Brilinta.
Valeant unveiled the sticker on its new psoriasis drug Siliq—and at $3,500 per month it’s the lowest for next-gen meds.
After years of pumping up its wellness content, Condé Nast has launched a new pharma-focused division to spur its reader-targeting powers and drive more custom…
Bristol-Myers Squibb pulled the rug out from under Opdivo TV ad spending in March after battling Merck’s rival med Keytruda near the top of the February charts.